TEURX
Price
$35.81
Change
+$0.42 (+1.19%)
Updated
Aug 21 closing price
Net Assets
1.26B
VIHAX
Price
$50.90
Change
+$0.55 (+1.09%)
Updated
Aug 21 closing price
Net Assets
21.87B
Interact to see
Advertisement

TEURX vs VIHAX

TEURX vs VIHAX Comparison Chart in %
View a ticker or compare two or three
VS
TEURX vs. VIHAX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TEURX is a Buy and VIHAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VIHAX has more cash in the bank: 21.9B vs. TEURX (1.26B). VIHAX pays higher dividends than TEURX: VIHAX (3.45) vs TEURX (2.09). TEURX was incepted earlier than VIHAX: TEURX (30 years) vs VIHAX (10 years). TEURX (2.01) is less costly to investors than VIHAX (0.16). TEURX is a more actively managed with annual turnover of: 51.25 vs. VIHAX (9.00). TEURX has a lower initial minimum investment than VIHAX: TEURX (1000) vs VIHAX (3000). VIHAX annual gain was more profitable for investors over the last year : 25.96 vs. TEURX (18.20). TEURX return over 5 years is better than : 76.54 vs. VIHAX (66.41).
TEURXVIHAXTEURX / VIHAX
Total Expense Ratio1.970.161,231%
Annual Report Gross Expense Ratio2.010.161,256%
Fund Existence30 years10 years-
Gain YTD10.55917.60160%
Front LoadN/AN/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRAN/AN/A-
Net Assets1.26B21.9B6%
Annual Yield % from dividends2.093.4560%
Returns for 1 year18.2025.9670%
Returns for 3 years69.6375.6392%
Returns for 5 years76.5466.41115%
Returns for 10 years116.66108.07108%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMOCX19.250.23
+1.21%
Victory RS Mid Cap Growth C
CIVHX22.290.17
+0.77%
American Funds Intl Vntg 529-F-3
GSYPX45.930.22
+0.48%
Goldman Sachs Small Cap Value P
PASTX68.290.18
+0.26%
T. Rowe Price Science & Tech Adv
JMNCX12.25-0.01
-0.08%
JPMorgan Research Market Neutral C